Medication info
Esriptin M Tablet 50/500 mg

Esriptin M Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202200334 · Approved 2022.01.20 · Insurance code 660703810

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose glycemic control is inadequate with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2, Contraindications, in Precautions for Use). 2. Patients receiving metformin: - For patients whose glycemic control is inadequate with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose glycemic control is inadequate with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General Precautions, in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications, in Precautions for Use).

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be used as an alternative when blood sugar control is inadequate with monotherapy of metformin or sitagliptin, or when these two medications are used together. Additionally, it can be used alongside metformin in cases where blood sugar control is difficult in combination with sulfonylurea, or when combined with thiazolidinedione therapy with metformin. If combination therapy with insulin and metformin is not effective, this medication may also be used to enhance therapeutic effects. It is used to improve blood sugar control alongside dietary management and exercise.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose glycemic control is inadequate with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2, Contraindications, in Precautions for Use). 2. Patients receiving metformin: - For patients whose glycemic control is inadequate with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose glycemic control is inadequate with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General Precautions, in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications, in Precautions for Use).

Precautions

This medication contains sitagliptin and metformin, and is primarily used for the treatment of type 2 diabetes. The sitagliptin component may cause severe hypersensitivity reactions, skin disorders, or acute pancreatitis in some patients, so if these symptoms occur within 3 months after starting treatment, consult a physician immediately. The metformin component can cause a rare yet potentially fatal side effect called lactic acidosis, and should not be used in patients with impaired kidney function or liver dysfunction. Especially, it should not be administered to patients with moderate to severe renal impairment, acute heart failure, or acute myocardial infarction, as well as to patients with severe infections or dehydration, and administration should also be discontinued around the time of diagnostic tests using iodine contrast agents. It is not recommended for use in pregnant women or those who may become pregnant, nursing mothers, or children under 18 years of age. While taking this medication, be cautious of hypoglycemic symptoms when using other medications that may cause blood sugar lowering, particularly when used in combination with insulin or sulfonylureas, as the risk of hypoglycemia may increase. Moreover, patients engaging in vigorous exercise or those with irregular eating habits or nutritional imbalances should be particularly cautious while taking this medication. Regular monitoring of kidney function and blood tests should be performed while taking this medication, and since vitamin B12 levels may decline, supplementation may be necessary if needed. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. In cases of undergoing surgery or when oral intake is restricted, this medication should be temporarily discontinued 48 hours prior to surgery and can be resumed only after confirming normal kidney function post-recovery. Patients taking this medication should immediately inform healthcare providers and discontinue use if they notice any unusual symptoms such as skin rash, hives, difficulty breathing, sudden joint pain, or blistering skin conditions. In the event of overdose, general symptomatic treatment may be provided along with dialysis if necessary. Although clinical trials have confirmed that this medication does not increase the risk of cardiovascular diseases, caution is warranted based on the patient’s condition. Therefore, this medication should be taken precisely according to the physician's prescription and instructions, and immediate consultation with healthcare providers should be sought if any unusual symptoms arise.

Side effects

Anaphylaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that is well-ventilated and kept at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.